Novel research suggests quitting smoking may help alleviate opioid crisis

Smoking is recognized as a leading cause of preventable disability and death. New research shows that as smokers increase their daily number of cigarettes, they report higher rates of chronic pain, more prescription opioid use, severe work limitations due to pain, and poor mental health. A novel study in the American Journal of Preventive Medicine, published by Elsevier, details the results of an analysis of nationally representative data from the US Agency for Healthcare Research and Quality’s Medical Expenditure Panel Survey (MEPS), revealing a strong link between smoking and opioid use and emphasizing the need for integrated treatment programs.

Summarizing key findings, the study’s authors William Encinosa, PhD, Didem Bernard, PhD, and R. Burciaga Valdez, PhD, MHSA, Division of Research and Modeling, Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality, and the McCourt School of Public Policy, Georgetown University, say, "Our research shows that adults who smoke 11-20 cigarettes per day use five times more prescription opioids than adults who never smoked. Adults who smoke more than a pack of cigarettes a day use almost three times as many opioids than adults who smoke 11-20 cigarettes per day. Thus, integrating smoking cessation programs into substance use treatments would be a prudent way of reducing prescription opioid use."

The team of researchers analyzed data from 2013 to 2021 from MEPS and the Centers for Disease Control and Prevention’s National Health Interview Survey. Findings show that although only 37% of the population has ever smoked, smokers account for 69% of annual prescription opioid use. Heavy smokers, just 12% of the population, use as many opioids as the 63% who have never smoked. Smokers also report higher rates of chronic pain, severe work limitations due to pain, and poor mental health.

This paper reports the first nationally representative estimates of the association between smoking, pain, and opioid use and how it has persisted from the height of opioid prescription use in 2013 to the recent low in 2021.

Opioid dispensing rates have declined from 81.3 prescriptions per 100 people in 2012 to 43.3 per 100 people in 2020. Many policy factors have led to this decline in opioid prescriptions, such as pill mill laws, state caps on the number of prescriptions per patient, state prescription drug monitoring systems, and the Centers for Disease Control and Prevention guidelines for chronic pain treatment, addressing the concern that high dosages and long-term use of opioids for chronic pain can lead to opioid use disorder and its adverse health outcomes. Despite this decline, there are still prescription opioid hotspots in the US.

The researchers conclude, "Combining smoking cessation with substance abuse treatment could be crucial in addressing the opioid epidemic. Many states and localities are attempting to ban various types of cigarettes. Our research shows that any resulting smoking cessation from these bans may also contribute to easing the opioid crisis."

Notes for editors

The article is “Heavy Versus Light Smoking: Its Association With Opioid Use, Chronic Pain, and Mental Health,” by William Encinosa, PhD, Didem Bernard, PhD, and R. Burciaga Valdez, PhD, MHSA (https://doi.org/10.1016/j.amepre.2024.07.010). It appears online in advance of the American Journal of Preventive Medicine, volume 67, issue 6 (December 2024), published by Elsevier.

The article is openly available for 30 days at https://www.ajpmonline.org/article/S0749-3797(24)00249-6/fulltext.

Full text of this article is also available to credentialed journalists upon request; contact Eileen Leahy, at +1 732 406 1313 or [email protected]. Journalists wishing to interview the authors should contact William Encinosa, PhD, at [email protected].

The study was funded by the Agency for Healthcare Research and Quality.

About the American Journal of Preventive Medicine

The American Journal of Preventive Medicine is the official journal of the American College of Preventive Medicine and the Association for Prevention Teaching and Research. It publishes articles in the areas of prevention research, teaching, practice and policy. Original research is published on interventions aimed at the prevention of chronic and acute disease and the promotion of individual and community health. The journal features papers that address the primary and secondary prevention of important clinical, behavioral and public health issues such as injury and violence, infectious disease, women's health, smoking, sedentary behaviors and physical activity, nutrition, diabetes, obesity, and alcohol and drug abuse. Papers also address educational initiatives aimed at improving the ability of health professionals to provide effective clinical prevention and public health services. The journal also publishes official policy statements from the two co-sponsoring organizations, health services research pertinent to prevention and public health, review articles, media reviews, and editorials. www.ajpmonline.org

엘스비어 소개

엘스비어는 첨단 정보와 의사결정 지원 분야를 선도하는 글로벌 기업입니다. 100년 넘게 과학과 의료의 발전을 뒷받침하며 인류의 더 나은 미래를 위해 노력해왔습니다. 우리는 전 세계 170개국의 대학 및 기업 연구자, 의사, 간호사, 차세대 보건의료 인력과 교육자들이 중요한 업무를 수행할 수 있도록 지원하고 있습니다. 우리는 신뢰할 수 있는 근거 기반의 과학과 의학 콘텐츠에 첨단 인공지능(AI) 기술을 접목한 핵심 인사이트와 혁신적인 솔루션을 제공함으로써, 이들의 더 나은 성과 달성을 돕고자 합니다. 우리는 제품과 조직 문화 전반에 포용성과 지속 가능성의 가치를 반영하고, 함께하는 커뮤니티와의 협력을 통해 이를 실천해 나가고 있습니다. 엘스비어 재단(Elsevier Foundation)은 세계 곳곳에서 연구 및 보건 분야의 협력 사업을 후원하고 있습니다.

엘스비어는 전문가 및 비즈니스 고객을 위한 정보 기반 분석 및 의사결정 도구를 제공하는 글로벌 기업 RELX의 계열사입니다. 자세한 내용은 www.elsevier.com에서 확인하실 수 있으며, SNS @ElsevierConnect를 통해 최신 소식도 실시간으로 받아보실 수 있습니다.